REGENERON PHARMACEUTICALS, INC. (REGN)
Pharmaceutical Preparations
Latest Price
$762.63
TTM P/E
18.62
Normalized P/E
18.72
Div Yield
0.35%
Book Value
302.15
P/B Ratio
2.52
Valuation metrics
adjust assumptions →EPS: $41.48
Book value / share: $287.82
Formula: √(22.5 × EPS × BVPS)
Graham Number
$518.29
32% downside
Norm. op. income: $4.0B (median of 7yr)
Tax rate: 11%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$389.06
49% downside
Base FCF: $4.1B (median of recent 5yr)
Growth: -3%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$428.04
44% downside
EPS: $41.48
Target P/E: 19×
Formula: EPS × P/E
P/E Fair Value
$788.12
+3% upside
Institutional Ownership
78.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.95M | $6.91B | 8.60% | +206.5K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.65M | $5.14B | 6.40% | -- | 2026-03-31 |
| STATE STREET CORP | 4.66M | $3.60B | 4.49% | +3.7K | 2026-03-31 |
| Dodge & Cox | 4.46M | $3.44B | 4.29% | -138.1K | 2026-03-31 |
| FRANKLIN RESOURCES INC | 2.72M | $2.10B | 2.62% | +162.1K | 2026-03-31 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.61M | $2.01B | 2.51% | +88.2K | 2026-03-31 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.18M | $1.68B | 2.09% | +227.7K | 2026-03-31 |
| Nuveen, LLC | 2.07M | $1.59B | 1.99% | +54.5K | 2026-03-31 |
| LOOMIS SAYLES & CO L P | 1.91M | $1.48B | 1.84% | -22.0K | 2026-03-31 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.84M | $1.42B | 1.77% | +1.17M | 2026-03-31 |